ADDF Prevention RFP
Supports dementia prevention research through precision risk reduction, combination treatment testing, and effectiveness comparisons.
The Alzheimer's Drug Discovery Foundation (ADDF) Prevention RFP funds clinical research targeting dementia risk reduction across three distinct categories: precision prevention and risk reduction, combination therapy studies, and comparative effectiveness research. ADDF, founded in 1998 and headquartered in New York, has distributed nearly $400 million to 792 programs in 21 countries and applies a…
Precision prevention, combination therapy studies, and comparative effectiveness research targeting dementia risk reduction. Anti-amyloid strategies and cholinesterase inhibitors excluded.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Guides for this application
All guides →Grants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
DocumentsGrant Work Plan Template: Work Packages, Gantt, Milestones, and Risks
Use this grant work plan template to structure work packages, tasks, owners, deliverables, Gantt timing, dependencies, and risk registers.
Submit & reportGrant Reporting Requirements: Post-Award Reports and Compliance
Learn what grant reporting requirements cover, how financial and performance reports work, what to track after an award, and how to avoid post-award compliance mistakes.
Write proposalGrant Letter of Intent: How to Write an LOI or Letter of Inquiry
Learn what a grant letter of intent is, when funders ask for LOIs or letters of inquiry, what to include, what to avoid, and how funder rules differ.
More from ADDF
All grants from this funder →ADDF Drug Development RFP
ADDF · Global / Multinational
Supports Alzheimer’s and dementia drug development from preclinical readiness to early clinical testing across diverse modalities.
ADDF Neuroimaging and CSF Biomarker RFP
ADDF · Global / Multinational
Funds new biomarkers for Alzheimer's and related dementias through PET ligands, MRI, spinal fluid, and brain activity measures.
ADDF-Harrington Scholar Program
🇺🇸ADDF · Global / Multinational
Funds academic Alzheimer's researchers with hit-to-lead and development-stage support plus therapeutic guidance.
Accelerating Drug Discovery for FTD RFP
ADDF · Global / Multinational
Funds lead optimization and in vivo testing for frontotemporal dementia candidates, including medicinal chemistry and preclinical studies.
Treat FTD Fund
ADDF · Global / Multinational
Funds early-stage clinical studies for frontotemporal dementia, including prevention trials for high-risk participants.
Similar grants
Browse the directory →
Prevention and management of chronic non-communicable diseases in children and young people
🇪🇺European Commission · European Union
Funds implementation research that helps children and young people prevent and manage chronic disease equitably.
EIC Pre-Accelerator
🇧🇬EIC · European Union
Funds early-stage European deep-tech firms developing evidence-ready prototypes and proof-of-concept solutions.
Deep Tech Development Aid (Aide au Développement Deeptech, ADD)
🇫🇷Bpifrance · France
Supports French deep-tech teams with practical innovation toward deployable outcomes.
NIH SBIR — Receipt (First Post-Reauthorization
🇺🇸NIH · United States
Supports United States. small businesses moving vision innovation from feasibility to development.
NIH STTR — Receipt (First Post-Reauthorization
🇺🇸NIH · United States
Supports small businesses partnering with research institutions on collaborative development pathways.
NIH CRP Commercialization Readiness Pilot
🇺🇸NIH SEED · United States
Offers late stage commercialization readiness support through NIH CRP for small firms advancing biomedical health solutions.